Press Contact: Nick Lazaridis, Ph.D.
AccuGenomics Announces New Additions to Scientific Advisory Board
– Preeminent experts in molecular diagnostics will provide guidance on the ongoing development of standardizing companion diagnostic technologies –
Wilmington, NC, June 8, 2017 – AccuGenomics, Inc., a diagnostic company based in Wilmington, NC, is pleased to announce the addition of two new members to its Scientific Advisory Board. Andrea Ferreira-Gonzalez, Ph.D., and Gregory Tsongalis, Ph.D., will advise AccuGenomics on the continued development of Standardized Nucleic Acid Quantification (SNAQ) and Standardized Next Generation Sequencing (STARSEQ), which are used in clinical studies investigating cancer and other diseases in which quantitative gene expression enables accurate diagnosis and can monitor responses to therapy. Both researchers are internationally recognized pioneers and experts in the field of molecular diagnostics.
“Dr. Ferreira-Gonzalez and Dr. Tsongalis are proven leaders in the advancement of molecular diagnostics and clinical research,” said Nick Lazaridis, Ph.D., President of AccuGenomics. “Throughout the course of their distinguished careers, they have continued to demonstrate a commitment to molecular diagnostics that furthers our understanding of critical disease categories.”
Dr. Andrea Ferreira-Gonzalez is a Professor of Pathology and the Chair of Molecular Diagnostics Division of Virginia Commonwealth University in Richmond, VA. A molecular diagnostics expert in the areas of genetics, oncology, personalized medicine, pharmacogenetics and infectious diseases in transplantation, Dr. Ferreira-Gonzalez has also played a major role in shaping national policy regarding the practice, reimbursement and guideline development for molecular diagnostics and molecular genetic testing. With over 80 publications in peer-reviewed literature, she is sought both nationally and internationally in the scientific, health management and business development communities as an accomplished leading authority.
Dr. Gregory Tsongalis is a Professor of Pathology and the Director of the Clinical Genomics and Advanced Technology Program at the Dartmouth-Hitchcock Medical Center in Lebanon, NH. A former President of the Association of Molecular Pathology, Dr. Tsongalis’s research includes developing novel technologies and approaches for biomarker discovery and molecular pathology using next-generation sequencing (NGS) and other advanced technologies. He has authored and/or edited five textbooks in the field of molecular pathology, published more than 100 peer reviewed manuscripts and has been invited to speak at both national and international meetings.
“As we continue to develop diagnostic tools and technologies, we welcome the opportunity to access the knowledge and vast expertise of both Dr. Ferreira-Gonzalez and Dr. Tsongalis. We could not be more proud to welcome them to our scientific advisory board,” said Tom Morrison, Ph.D., Chief Scientific Officer of AccuGenomics.
For more information about AccuGenomics, their diagnostic tools and their pipeline, please visit www.accugenomics.com.
AccuGenomics, Inc. is a diagnostic company headquartered in Wilmington, NC. Founded in 2010 by clinical researchers in the life sciences and diagnostic industries, AccuGenomics grew from a collaboration with the University of Toledo and the Innovative Molecular Analysis Technologies Program of the National Institutes of Health. Today, AccuGenomics is committed to improving patient outcomes by providing standardization technologies for multi gene expression tests that accurately diagnose, monitor and inform the treatment of diseases. Their leading technologies include Standardized Nucleic Acid Quantification (SNAQ), for use in quantitative polymerase chain reaction (PCR) platform analysis, and Standardized RNA Sequencing (STARSEQ), which ensures quality in next-generation sequencing (NGS). For more information or to discuss a partnership with AccuGenomics, please visit www.accugenomics.com or call 910.332.6522.